1146699-59-3

Basic information

• Product Name: Pentanenitrile, 5,5,5-trifluoro-2-[[(1R)-1-phenylethyl]aMino]-
• Synonyms: Pentanenitrile, 5,5,5-trifluoro-2-[[(1R)-1-phenylethyl]aMino]-;5,5,5-Trifluoro-2-[[(1R)-1-phenylethyl]amino]-pentanenitrile
• CAS NO: 1146699-59-3
• Molecular Weight: 256.271
• Mol File: 1146699-59-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Pentanenitrile, 5,5,5-trifluoro-2-[[(1R)-1-phenylethyl]aMino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanenitrile, 5,5,5-trifluoro-2-[[(1R)-1-phenylethyl]aMino]-(1146699-59-3)
• EPA Substance Registry System: Pentanenitrile, 5,5,5-trifluoro-2-[[(1R)-1-phenylethyl]aMino]-(1146699-59-3)

Safety Data

• Hazardous Substances Data: 1146699-59-3(Hazardous Substances Data)

Upstream product

• 773837-37-9 sodium cyanide 
• 406-87-1 4,4,4-trifluorobutanal 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 7677-24-9 trimethylsilyl cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 1146699-60-6 5,5,5-trifluoro-2-(R-1-phenylethylamino)pentanamide 

Relevant articles and documents

Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable γ-secretase inhibitor

During the course of our research efforts to develop a potent and selective γ-secretase inhibitor for the treatment of Alzheimer's disease, we investigated a series of carboxamide-substituted sulfonamides. Optimization based on potency, Notch/amyloid-β precursor protein selectivity, and brain efficacy after oral dosing led to the discovery of 4 (BMS-708163). Compound 4 is a potent inhibitor of γ-secretase (Aβ40 IC50 = 0.30 nM), demonstrating a 193-fold selectivity against Notch. Oral administration of 4 significantly reduced Aβ40 levels for sustained periods in brain, plasma, and cerebrospinal fluid in rats and dogs.

Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production

The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with β-amyloid peptide.